SIGN: a Phase II, open-label, randomized study comparing gefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

被引：1
|
作者：
Cufer, T
Vrdoljak, E
机构：
[1] Clin Hosp Split, Split, Croatia
[2] Inst Oncol, Ljubljana, Slovenia
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [21] Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    Socinski, MA
    Schell, MJ
    Peterman, A
    Bakri, K
    Yates, S
    Gitten, R
    Unger, P
    Lee, J
    Lee, JH
    Tynan, M
    Moore, M
    Kies, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1335 - 1343
  • [22] Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study
    Crino, L.
    Boyer, M.
    Eberhardt, W. E.
    Baliko, Z.
    Smit, E. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] SECOND-LINE CHEMOTHERAPY (CT) WITH DOCETAXEL IN ELDERLY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS: A PHASE II STUDY
    Bernardini, I.
    Tibaldi, C.
    Chella, A.
    Galli, L.
    Russo, F.
    Toma, G.
    Tempestini, F.
    Santolicandro, A. M.
    Coltelli, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 34 - 34
  • [24] A Phase IV, multicenter, non-randomized, open-labeled study to evaluate the efficacy of Gefitinib (IRESSA®) as a second-line therapy in Korean patients with non-small cell lung cancer (NSCLC)
    Lee, Kwan-Ho
    Lee, Kye-Young
    Jeon, Young-June
    Jung, Maan-Hong
    Son, Choon-Hee
    Lee, Min-Ki
    Ryu, Jeong-Seon
    Yang, Sei-Hoon
    Lee, Jae-Cheol
    Kim, Young-Chul
    Kim, Sun-Young
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S692 - S693
  • [25] Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer
    Manegold, Christian
    Koschel, Gabriele
    Hruska, Dagmar
    Schott-von-Romer, Kathrin
    Mezger, Joerg
    Pilz, Lothar Richard
    CLINICAL LUNG CANCER, 2007, 8 (04) : 245 - 251
  • [26] Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
    Morgillo, Floriana
    Fasano, Morena
    Della Corte, Carminia Maria
    Sasso, Ferdinando Carlo
    Papaccio, Federica
    Viscardi, Giuseppe
    Esposito, Giovanna
    Di Liello, Raimondo
    Normanno, Nicola
    Capuano, Annalisa
    Berrino, Liberato
    Vicidomini, Giovanni
    Fiorelli, Alfonso
    Santini, Mario
    Ciardiello, Fortunato
    ESMO OPEN, 2017, 2 (02)
  • [27] Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer
    Belani, CP
    Einzig, A
    Bonomi, P
    Dobbs, T
    Capozzoli, MJ
    Earhart, R
    Cohen, LJ
    Luketich, JD
    ANNALS OF ONCOLOGY, 2000, 11 (06) : 673 - 678
  • [28] A Prospective Phase I / II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB / IV Non-Small Cell Lung Cancer
    Kroeber, Vinzenz
    Nagel, Sylke
    Schuette, Wolfgang
    Blankenburg, Thomas
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 435 - 443
  • [29] Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancer
    Reck, M
    Gatzemeier, U
    RESPIRATORY MEDICINE, 2005, 99 (03) : 298 - 307
  • [30] Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
    Oka, M
    Fukuda, M
    Nagashima, S
    Fukuda, M
    Kinoshita, A
    Soda, H
    Doi, S
    Narasaki, F
    Suenaga, M
    Takatani, H
    Nakamura, Y
    Kawabata, S
    Tsurutani, J
    Kanda, T
    Kohno, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (06) : 446 - 450
12345